Le Lézard
Classified in: Health
Subjects: PDT, TDS, FVT

Together with Siemens Healthineers, Varian Demonstrates Commitment to Embracing Innovation and Enhancing Outcomes at ASTRO 2023

-          Participating in ASTRO, being held from October 1-4, 2023, in San Diego, California 
-          Introducing five new product iterations across the entire portfolio
-          Expanding the HyperSight imaging solution to TrueBeam and Edge radiotherapy systems*

PALO ALTO, Calif., Sept. 28, 2023 /PRNewswire/ -- Varian, a Siemens Healthineers company, is showcasing technologies that reflect its continued commitment to embracing innovation and enhancing outcomes for cancer patients at this year's 2023 American Society for Radiation Oncology (ASTRO) annual meeting, taking place from October 1-4 in San Diego, California.

Cancer care is complex, and providers worldwide are forced to navigate the challenges of fragmented healthcare delivery systems. As a Siemens Healthineers company, Varian is building on its legacy as a radiotherapy leader and evolving to enable comprehensive cancer care by providing innovative, increasingly integrated solutions.

"Radiotherapy is a vital part of most cancer patients' treatment and, thanks to the collaboration and input Varian users have provided, our technology has advanced significantly over the past couple of decades," said Arthur Kaindl, Head of Varian. "At Varian, we see tremendous opportunities to build on our leadership in radiotherapy and advance our mission to help create a world without fear of cancer. We are confident that our continued investment in innovation along the entire cancer care continuum will allow providers to treat more patients in need, more efficiently, earlier in their cancer journey ? ultimately, creating the opportunity to enhance outcomes for patients around the world." 

The solutions Varian will be highlighting at ASTRO support the company's commitment to embracing innovation and enhancing outcomes by:

Connecting the power of imaging 

By joining forces with Siemens Healthineers, a global leader in imaging, Varian is working to expand its imaging capabilities to provide solutions with improved accuracy and quality. Examples that will be showcased at ASTRO include:

Unlocking the power of software 
Varian is pioneering integrated software solutions to reduce redundancies and streamline workflows to unify patient care pathways and ultimately improve outcomes. Key portfolio highlights include:

Advancing evidence-based medicine 
By investing in evidence generation, Varian is working to advance the standard of care. Varian's commitment to improving patient outcomes and enhancing quality of life continues to be reinforced by the many oral, panel, and poster presentations to be given at ASTRO that build on new and existing clinical evidence across several treatment areas.

Throughout the conference, experts will provide one-on-one product demonstrations at the Varian booth as well as host a User Meeting event the day before the Annual Meeting officially begins.

*FDA 510(k) pending. Not available for sale in all markets.

VARIAN, ARIA, ECLIPSE, ETHOS, HYPERSIGHT, EDGE, and TRUEBEAM are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat. & Tm. Off. MAGNETOM Free.Max is a trademark of Siemens Healthcare GmbH registered U.S. Pat. & Tm. Off. Siemens Healthineers is a trademark of Siemens Trademark GmbH & Co. KG registered U.S. Pat. & Tm. Off.

About Varian
At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey ? from screening to survivorship. From advanced imaging and radiation therapy, to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com.  

Press Contact
Mo Tracy
Varian Corporate Communications
[email protected]


These press releases may also interest you

at 12:35
Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced positive preclinical data for its lead small molecule QPCTL inhibitor, SC-2882. The data was also presented today by...

at 12:30
Blueprint Medicines Corporation today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis (SM) at the 65th American Society of Hematology (ASH)...

at 12:05
Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented details from the Rallybio Fetal and...

at 12:05
Genmab A/S and AbbVie today announced new data from the ongoing phase 1/2 EPCOREtm NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall...

at 12:00
AbbVie and Genmab A/S announced today that adult patients with relapsed/refractory (R/R) follicular...

at 11:35
bluebird bio, Inc. ("bluebird bio" or "bluebird") today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel...

News published on and distributed by: